RxDoctor Payments Data

Richard Sowell, MD

Internal Medicine · Chattanooga, TNNPI 1386621944

Payments from drug & device makers

$11,887in general payments, 2019–2025

Across 762 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$876
  • AbbVie$859
  • Lilly USA, LLC$847
  • AstraZeneca$842
  • Amgen$818
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$11,77299%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,887 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$242,192
Medicare patients
529
Services billed
3,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$224,932
OzempicSemaglutide99$111,965
JanuviaSitagliptin Phosphate106$94,941
TradjentaLinagliptin32$42,184
JardianceEmpagliflozin30$35,087
XareltoRivaroxaban30$34,596
FarxigaDapagliflozin Propanediol35$32,113
RybelsusSemaglutide20$29,312
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,222
Tresiba Flextouch U-200Insulin Degludec32$20,844
Tresiba Flextouch U-100Insulin Degludec28$17,589
MounjaroTirzepatide13$16,908
OxycontinOxycodone Hcl12$16,248
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$15,930
Rivastigmine32$12,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$876$224,932230 claims
Novo NordiskOzempic, Rybelsus$2,075$141,278119 claims
MerckJanuvia, Lagevrio (Eua), Janumet$216$110,537135 claims
Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat$706$89,03473 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$453$45,14373 claims
Johnson & JohnsonXarelto$554$34,59630 claims
AstraZenecaFarxiga$842$32,11335 claims
Lilly USA, LLCMounjaro$847$16,90813 claims
Kowa Pharmaceuticals America, Inc.Livalo$37$4,50812 claims
AbbVieSynthroid$859$3,33645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →